The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1400
Influenza Vaccine for 2012-2013
The full article is available to subscribers Subscriber Login   

Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and its complications. A new vaccine is available for the current season. Chemoprophylaxis and treatment of influenza was discussed in an earlier issue.1

VACCINE COMPOSITION — This year’s seasonal trivalent influenza vaccine contains the following three strains: A/California/7/2009 H1N1-like (derived from the pandemic 2009 influenza virus), A/Victoria/361/2011 H3N2-like, and B/Wisconsin/1/2010-like. The H1N1 strain is the same as in last year’s vaccine. The H3N2 and B strains are new this year.2

LIVE VS. INACTIVATED VACCINE — FluMist, the intranasal live attenuated influenza vaccine (LAIV), is recommended for use only in healthy, non-pregnant persons 2-49 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Influenza Vaccine for 2012-2013
Article code: 1400a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian